Adial Pharmaceuticals IncNASDAQ:ADIL
- LAST PRICE1.0098
- TODAY'S CHANGE (%)-0.0002 (-0.0198%)
- Bid / Lots1.0000/ 41
- Ask / Lots1.0100/ 14
- Open / Previous Close0.9990 / 1.0100
- Day Range
- 52 Week Range
- Volume71,831
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ADIL |
|---|---|---|
| 09:32 ET | 6631 | 1.0001 |
| 09:33 ET | 1059 | 1.0009 |
| 09:35 ET | 100 | 1.016 |
| 09:37 ET | 150 | 1.01 |
| 09:39 ET | 2000 | 1.02 |
| 09:48 ET | 300 | 1.01 |
| 09:50 ET | 770 | 1.0001 |
| 09:51 ET | 1290 | 1.01 |
| 10:04 ET | 2025 | 1 |
| 10:06 ET | 500 | 1 |
| 10:13 ET | 160 | 1 |
| 10:31 ET | 3699 | 0.9902 |
| 10:54 ET | 5100 | 0.9951 |
| 10:56 ET | 2400 | 0.9998 |
| 11:12 ET | 512 | 1.0099 |
| 11:14 ET | 570 | 1.0097 |
| 11:16 ET | 500 | 1.005 |
| 11:18 ET | 3232 | 1.0002 |
| 11:20 ET | 400 | 1 |
| 11:32 ET | 10450 | 1.0001 |
| 11:39 ET | 100 | 1.005 |
| 11:43 ET | 133 | 1.01 |
| 12:01 ET | 100 | 1.005 |
| 12:15 ET | 114 | 1.01 |
| 12:19 ET | 249 | 1 |
| 12:21 ET | 100 | 1 |
| 12:32 ET | 111 | 1.0065 |
| 12:50 ET | 100 | 1.005 |
| 01:08 ET | 5000 | 1 |
| 01:13 ET | 100 | 1.01 |
| 01:24 ET | 500 | 1.0004 |
| 01:26 ET | 1980 | 1 |
| 01:27 ET | 100 | 1.01 |
| 01:29 ET | 100 | 1 |
| 01:33 ET | 100 | 1.005 |
| 01:38 ET | 300 | 1.0005 |
| 01:44 ET | 1615 | 1.0099 |
| 01:47 ET | 500 | 1.0098 |
Nov 14, 2024
Adial Pharmaceuticals Announces Positive Topline Results from the AD04-103 Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder, from 8:30AM ET on Thursday Nov 14, 2024 by Dow Jones
8:30AM ET on Thursday Nov 14, 2024 by Dow JonesDJ Adial Pharmaceuticals Initiated at Buy by Rodman & Renshaw, from 7:02AM ET on Thursday Nov 14, 2024 by Dow Jones
7:02AM ET on Thursday Nov 14, 2024 by Dow Jones
Nov 13, 2024
Adial Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update, from 8:30AM ET on Wednesday Nov 13, 2024 by Dow Jones
8:30AM ET on Wednesday Nov 13, 2024 by Dow Jones
Nov 5, 2024
Press Release: Adial Pharmaceuticals Appoints Vinay Shah as Chief Financial Officer, from 8:30AM ET on Tuesday Nov 05, 2024 by Dow Jones
8:30AM ET on Tuesday Nov 05, 2024 by Dow JonesAdial Pharmaceuticals Appoints Vinay Shah as Chief Financial Officer, from 8:30AM ET on Tuesday Nov 05, 2024 by Dow Jones
8:30AM ET on Tuesday Nov 05, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Adial Pharmaceuticals Inc | 6.5M | -0.2x | --- |
Viracta Therapeutics Inc | 6.3M | -0.1x | --- |
Transcode Therapeutics Inc | 6.6M | 0.0x | --- |
Virpax Pharmaceuticals Inc | 6.6M | -0.1x | --- |
Brainstorm Cell Therapeutics Inc | 6.6M | -0.4x | --- |
CNS Pharmaceuticals Inc | 6.2M | 0.0x | --- |
Company Information
Adial Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of treatments for addictions and related disorders. The Company’s lead investigational new drug product, AD04, is a genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder (AUD) in heavy drinking patients. AD04 is investigated in the Company’s ONWARD pivotal Phase III clinical trial for the treatment of AUD in subjects with certain target genotypes (estimated to be approximately one-third of the AUD population) identified using the Company’s companion diagnostic genetic test. AD04 is also used for the treatment of other addictive disorders, such as Opioid Use Disorder, obesity, smoking, and other drug addictions. The Company’s wholly owned subsidiary is Purnovate, Inc.
Contact Information
- Headquarters
- 1180 SEMINOLE TRAIL, SUITE 495CHARLOTTESVILLE, VA, United States 22901
- Phone
- 434-422-9800
- Fax
- 302-655-5049
Executives
- Lead Independent Chairman of the Board
- Kevin Schuyler
- President, Chief Executive Officer, Director
- Cary Claiborne
- Chief Financial Officer
- Vinay Shah
- Chief Operating Officer, Director
- Tony Goodman
- Independent Director
- J. Kermit Anderson
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $6.5M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 6.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.30 |
EPS | $-4.49 |
Book Value | $2.45 |
P/E Ratio | -0.2x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
